A few nonsurgical treatments for urinary incontinence in women provide modest improvement at best, and expensive drug therapies are really no more effective than pelvic floor muscle and bladder training, say the findings of a systematic review of 96 randomized controlled trials and three systematic reviews published in English from 1990 to 2007.
A few nonsurgical treatments for urinary incontinence in women provide modest improvement at best, and expensive drug therapies are really no more effective than pelvic floor muscle and bladder training, say the findings of a systematic review of 96 randomized controlled trials and three systematic reviews published in English from 1990 to 2007.
The only treatments that really seem to make any difference are pelvic floor muscle training plus bladder training, which, compared with regular care, had a pooled risk difference of 0.13 (95% CI, 0.07 to 0.20), and oxybutynin or tolterodine, which had a pooled risk difference compared with placebo of 0.18 (95% CI, 0.13–0.22). Pelvic floor muscle training alone provided relief or resolution, but did so inconsistently across studies, as did transdermal or vaginal estrogen. Compared with placebo, duloxetine provided improvement (pooled risk difference 0.11; 95% CI, 0.07–0.14), but did not resolve urinary incontinence. Electrical stimulation and adrenergic drugs failed to provide any improvement, and oral hormones actually made urinary incontinence worse.
Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: randomized, controlled trials of nonsurgical treatment for urinary incontinence in women. Ann Intern Med. 2008;148:459-473.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More